Combivent Unit Dose Vials

Combivent Unit Dose Vials contains Ipratropium Bromide (equivalent to 500 micrograms per vial) and is presented as a healthcare product. It is supplied in pack sizes of 2.5ml x10 and 2.5ml x20.

It is classified as a non-prescription medicine, so no prescription is needed to order it. Under Malaysian rules for medicine information, this page carries product, safety and handling information only.

You can consult a doctor or pharmacist online on DoctorOnCall about this product before or after you order. Every order is checked by a registered pharmacist before it is delivered. Always read the label and the leaflet supplied with the pack.

Combivent Unit Dose Vials must only be used with a nebuliser device as instructed by your doctor or respiratory therapist, not taken orally or used in any other way. The contents of one vial are typically emptied into the nebuliser chamber, either used undiluted or diluted as directed, and the mist is inhaled through a mouthpiece or face mask over several minutes until the chamber is empty, with the device cleaned after each use according to the manufacturer’s instructions.

The typical adult dose is the contents of one unit dose vial administered via nebuliser, repeated as needed and as prescribed by your doctor, usually up to a maximum number of times per day; children require a different, doctor-determined dose. Do not use more frequently or in higher amounts than prescribed, and seek urgent medical attention if breathing difficulty is not relieved or worsens despite treatment.

Combivent Unit Dose Vials remain stable until the expiry date printed on the individual vial and outer packaging when stored correctly and protected from light; each vial is intended for single use and any unused solution remaining after nebulisation should be discarded rather than stored for later use.

Store the vials in their protective foil pouch, away from direct light, at room temperature below 30°C, and do not remove a vial from its pouch until ready for immediate use. Keep out of reach of children, and discard any vial that has been exposed to light for a prolonged period or shows discolouration.

• Known hypersensitivity to ipratropium bromide, salbutamol, atropine-like compounds, or any excipient in the formulation
• Hypertrophic obstructive cardiomyopathy or certain types of tachyarrhythmia, where beta-agonists should be used with caution or avoided
• Caution required in patients with narrow-angle glaucoma, as contact with the eyes may worsen the condition
• Caution in patients with bladder outlet obstruction or urinary retention due to the anticholinergic component
• Use with care in patients with uncontrolled hyperthyroidism, cardiovascular disease, or diabetes

• Other beta-adrenergic bronchodilators or anticholinergic medicines may increase the risk of combined side effects if used together without medical guidance
• Beta-blockers may reduce the bronchodilator effect and should generally be avoided in patients with reversible airway disease
• Monoamine oxidase inhibitors and tricyclic antidepressants may increase cardiovascular effects of salbutamol
• Diuretics that lower potassium (such as certain thiazides) may worsen salbutamol-related drops in blood potassium
• Inform your doctor of all other inhaled or nebulised medicines you are using

• Always use Combivent with a properly functioning, clean nebuliser device
• Avoid letting the mist come into direct contact with your eyes
• Rinse your mouth after use to reduce dryness and throat irritation
• Keep track of how often you need to use it — increasing frequency may signal your asthma or COPD is not well controlled and needs medical review
• Do not exceed the number of nebulised doses per day advised by your doctor
• Carry your regular reliever medicine as advised, and seek emergency care for severe breathing difficulty

Combivent Unit Dose Vials are generally used for short-term relief during acute worsening of asthma or COPD symptoms rather than as a first-line, everyday maintenance treatment, and patients on this therapy should have their overall respiratory condition reviewed periodically by their doctor. An increasing need for nebulised bronchodilator treatment can indicate poorly controlled underlying disease and should prompt an earlier medical review rather than simply repeating doses.